论文部分内容阅读
急性早幼粒细胞白血病（ APL）是急性髓细胞白血病中的一种特殊类型，99％的 APL有染色体t（15；17）（q22；q12）易位和早幼粒白血病基因与维甲酸受体基因融合基因的形成。近年来，由于亚砷酸等靶向药物的应用，APL的治疗效果大大提高。但亚砷酸应用的同时所带来的不良反应也引起了越来越多的关注，尤其是对肝脏，进而影响着亚砷酸在肝脏转化为活性产物中的疗效。该文针对亚砷酸治疗APL的肝功损害特点以及保肝药物应用的现状进行了综述，旨在合理化监测肝功能及保肝药物的应用，以使亚砷酸的疗效达到最佳。“,”The acute promyelocytic leukemia(APL) is a special kind of acute myelogenous leukemia, 99% of which is characterized with t (15;17)(q22;q12)chromosomal translation,leading to the synthesis of a fusion protein PML-RARα.Since the application of targeted drug like arsenite, the outcome of the APL has improved dramatically .However,arsenite has a toxicity profile that is mainly reflected in liver .In recent years,the increasing attentions are focused on side effects brought by arsenite application especially in liver , the toxicity of which further effects its efficacy .Here is to make a review of the characteristics of hepatic im-pairment and application of hepatoprotective drugs in APL treated by arsenite in order to obtain better thera-peutic effect.